Navigation Links
Canopus BioPharma Strengthens its CB1400 Platform Technology for Mucositis and Oncology Treatments Through License Agreement With Wisconsin Alumni Research Foundation
Date:6/18/2008

, is currently in phase II clinical development by Canopus as an anti-mucositis preventative agent in patients receiving radio- and/or chemotherapy treatment. CB1400 alone and in combination with both cisplatin and cetuximab (Erbitux), has also been shown to inhibit tumor growth in two mice models of lung cancer, thus demonstrating the broad capabilities of this compound in the treatment of cancer.

About the Wisconsin Alumni Research Foundation:

The Wisconsin Alumni Research Foundation (WARF) supports research at the University of Wisconsin-Madison by protecting the intellectual property of University faculty, staff and students, and licensing inventions resulting from their work. Through these efforts, university ideas benefit the public by bringing resources back to the university to continue the cycle of investment, research and invention. WARF (http://www.warf.org) was established in 1925 as the first university-based technology transfer office in the world.

About Canopus BioPharma, Inc.:

Canopus BioPharma, Inc. (OTC: CBIA) is dedicated to providing the safest, most cost effective and efficacious pharmaceutical products and assay methods in the areas of infectious disease, radiation protection, cancer, and addiction. With innovative science, proven research and development leadership, and superior products and compounds, Canopus BioPharma has, since 2001, been committed to becoming a market trend setter in a new era of healthcare. In addition, the Company is a world leader in the development of novel camelid antibody products to provide unique avenues of progress and improvement in assay methods and monitoring capabilities for physicians, patients and researchers, initially for food chain protection applications. Canopus maintains staff in Australia, South Africa, Ireland, Panama and the USA. Additional information on the Company is available at '/>"/>

SOURCE Canopus BioPharma, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. WallSt.net (www.wallst.net) Updates the Investment Community Through an All-New Interview With RegeneRx Biopharmaceuticals CEO
2. Nabi Biopharmaceuticals Announces Second Quarter 2007 Financial Results
3. Nabi Biopharmaceuticals Announces Continued Positive NicVAX Phase 2b Data at Nine Months
4. Keryx Biopharmaceuticals to Present at William Blair & Company Small-Cap Growth Stock Conference
5. Morria Biopharmaceuticals Plc Initiates Phase I Clinical Study of MRX-4 in Allergic Rhinitis
6. Keryx Biopharmaceuticals, Inc. Announces Positive Preliminary Phase 2 Data on KRX-0401 in Patients with Chemo-Insensitive Rare Sarcoma
7. Nabi Biopharmaceuticals Announces Successful Completion of NicVAX(R) Phase 2b Trial; Drug Shows Statistically Significant Rates of Smoking Cessation and Continuous Long-Term Smoking Abstinence at 12 Months
8. Inspiration Biopharmaceuticals Announces Filing of IND for Novel Recombinant Factor IX Product, IB1001, for the Treatment of Hemophilia B
9. Immunosyn Announces Biozyme Labs Receipt of MHRA Manufacturing License Approval in Europe for the Biopharmaceutical SF-1019
10. Keryx Biopharmaceuticals, Inc. Announces Phase 1 and Phase 2 Data on KRX-0401 (Perifosine) in Patients with Relapsed/Refractory Multiple Myeloma at 49th Annual Meeting of American Society of Hematology
11. XTL Biopharmaceuticals Presents Data Regarding its Hepatitis C Virus Small Molecule Program at Hep Dart 2007 - an International Scientific Conference on Viral Hepatitis
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/27/2015)... , Feb. 27, 2015  Organovo Holdings, ... company focused on delivering breakthrough 3D bioprinting technology, ... and Chief Executive Officer, will present live at ... invite you to join us for this Company ... updates on our commercial launch of the exVive3D ...
(Date:2/27/2015)... , Feb. 27, 2015  Uroplasty, Inc. (NASDAQ: ... manufactures and markets innovative proprietary products to treat voiding ... 27th Annual ROTH Conference on Tuesday, March 10, 2015. ... Brett Reynolds , Chief Financial Officer, will present at ... on one at the conference at the Ritz Carlton ...
(Date:2/27/2015)... JERUSALEM , Feb. 27, 2015  Chiasma, Inc., ... lead product for the orphan condition acromegaly, today announced ... round. Participants in the financing included new investors Rock ... chip public investment fund, as well as existing investors ... and ARCH Venture Partners. Chiasma intends ...
Breaking Medicine Technology:Organovo Holdings, Inc. to Provide Corporate Update and Investor Presentation in a Live, Interactive Webcast on March 5th 2Organovo Holdings, Inc. to Provide Corporate Update and Investor Presentation in a Live, Interactive Webcast on March 5th 3Organovo Holdings, Inc. to Provide Corporate Update and Investor Presentation in a Live, Interactive Webcast on March 5th 4Uroplasty to Participate in the 27th Annual ROTH Conference 2Chiasma Announces Completion of $70 Million Series E Financing 2Chiasma Announces Completion of $70 Million Series E Financing 3
... ,SARAH, - a French national collaborative randomized controlled ... sorafenib in advanced hepatocellular carcinoma is now open ... a new randomized controlled trial to directly compare ... (SIR-Spheres ® microspheres; Sirtex Medical Limited, Australia) ...
... 2, 2012  On February 2, at the Late-Breaking Science Session ... the TREVO Study ( T hrombectomy ... O cclusions in acute ischemic stroke). This ... clot-removing stent retriever technology. Sixty patients were enrolled by seven ...
Cached Medicine Technology:New Study of Primary Liver Cancer Seeks to Enroll 400 French Patients 2New Study of Primary Liver Cancer Seeks to Enroll 400 French Patients 3New Study of Primary Liver Cancer Seeks to Enroll 400 French Patients 4Stryker Presents Results of the TREVO Prospective Clinical Study at the International Stroke Conference 2
(Date:2/28/2015)... In recent years Medical Marijuana has continuously ... as a way for them to expand their patient base ... medicine. Since the FDA still lists Cannabis as a Schedule ... licensed physicians that can help guide them when recommending ... in Santa Cruz, CA is a leader in the ...
(Date:2/28/2015)... With their commitment to achieving physical results and ... to their already robust library of oblique exercises. “Rope ... as, is often performed on a stationary piece of ... relatively safe manner and can be performed by individuals ... of “Rope Pulls” is located in the oblique exercises ...
(Date:2/28/2015)... 28, 2015 Mew and Company, a ... they now provide business consulting services in addition to ... tax planning and succession planning. Company finances are a ... professionals. On top of this, complex Canadian tax laws ... accounting. As a result, Mew and Company works to ...
(Date:2/28/2015)... For those people who are unable ... Mesothelioma Applied Research Foundation (Meso Foundation) will broadcast ... starting at 9:30 AM. , The live broadcast is ... can be accessed through any browser on a computer ... Symposium is a unique event that covers important treatment ...
(Date:2/28/2015)... Dr. Perry Patel , a ... recently announced a special offer for the Zoom!® Chairside ... for new and established patients at his Pismo Beach dentist office. ... white smile, Dr. Patel and his staff are offering ... from the regular price of $450. , Zoom! whitening ...
Breaking Medicine News(10 mins):Health News:Reputable Cannabis Doctor In Santa Cruz and Monterey Joins the Medical Cannabis Network 2Health News:Vancouver Corporate Tax Accountants Now Provide Business Consulting Services 2Health News:Mesothelioma Cancer Research Foundation Broadcasting Symposium Live 2Health News:Pismo Beach Dentist Announces Special for Zoom! Teeth Whitening 2
... , OCEANSIDE, Calif. , Feb. 4 ... International Association for Life Quality (IALQ) – a national ... quality life for those with developmental disabilities – announced ... available to underserved families with a child with autism ...
... , , XI,AN, China ... Inc. (OTC Bulletin Board: HFGB), a leading,developer and producer of ... and food production, today announced,preliminary 2009 results and provided guidance ... anticipates revenues between $13,million to $14 million for ...
... U.S.A. (Feb. 4, 2010) A novel finding, described today (Feb. ... from the National Cancer Institute, The University of Texas Health Science ... clue as to how genes can have what you might call ... but they can be cut and spliced to make different proteins, ...
... ... Easy” explains cloud computing technology and how it drives social change , ... Morgantown, WV (PRWEB) February 4, ... TeamHost ™ online platform for creating SaaS applications, has launched its new portal for ...
... using them or not, , THURSDAY, Feb. 4 (HealthDay ... (COPD) are often given inhaled corticosteroids to help ease ... these drugs may be of only limited benefit. , ... treat the symptoms of COPD, they have also been ...
... , NAPERVILLE, Ill. , Feb. ... the Illinois Supreme Court has struck down critically needed medical ... state and restoring predictability to our broken medical liability system. ... clear will of the people of Illinois who ...
Cached Medicine News:Health News:Scholarships Available for Special Needs Life Quality Plans 2Health News:Huifeng Bio-Pharmaceutical Provides Preliminary 2009 Financial Results and 2010 Guidance 2Health News:Huifeng Bio-Pharmaceutical Provides Preliminary 2009 Financial Results and 2010 Guidance 3Health News:Scientists ID a protein that splices and dices genes 2Health News:Virtual Global Launches Cloudipedia.com to Help Cloud Computing Newbies 2Health News:Virtual Global Launches Cloudipedia.com to Help Cloud Computing Newbies 3Health News:Steroids May Be Overrated in Treatment of COPD 2Health News:Steroids May Be Overrated in Treatment of COPD 3Health News:Statement From IHA President Maryjane A. Wurth on Illinois Supreme Court Medical Liability Ruling 2
... immobilization and cervical spine care, one piece may ... that the most important function of a cervical ... you may not know is that independent studies ... immobilization over the leading one-piece rigid collar, and ...
... Our "Stock Saver" hip abduction orthosis provides ... Classic Hip with one major difference. Our design ... be easily adapted for use in either left ... stock lefts and rights. A comfortable neoprene padding ...
... This classic orthosis provides firm support ... post operative, primary or revision total hip ... brace and acts as a wicking interface. ... of our patented Infinity or Genesis joints. ...
... provides stabilization for patients prone to chronic ... for anterior or posterior hip dislocation, congenital ... adductors secondary to hemiplegia or cerebral palsy. ... flexion/extension ROM control from 0° to 120° ...
Medicine Products: